Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) will announce its earnings results on Tuesday, October 31st. Analysts expect the company to announce earnings of ($0.22) per share for the quarter.

Shares of Eyegate Pharmaceuticals, Inc. (EYEG) opened at 1.0401 on Tuesday. The company’s market capitalization is $17.89 million. Eyegate Pharmaceuticals, Inc. has a one year low of $0.90 and a one year high of $3.90. The stock has a 50 day moving average price of $1.16 and a 200 day moving average price of $1.16.

ILLEGAL ACTIVITY WARNING: “Eyegate Pharmaceuticals, Inc. (EYEG) to Release Quarterly Earnings on Tuesday” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2017/10/24/eyegate-pharmaceuticals-inc-eyeg-to-release-quarterly-earnings-on-tuesday.html.

Separately, HC Wainwright set a $6.00 price target on shares of Eyegate Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 2nd.

An institutional investor recently raised its position in Eyegate Pharmaceuticals stock. Vanguard Group Inc. lifted its position in shares of Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) by 0.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 247,319 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,988 shares during the period. Vanguard Group Inc. owned about 2.27% of Eyegate Pharmaceuticals worth $339,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 12.99% of the company’s stock.

Eyegate Pharmaceuticals Company Profile

Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.

Receive News & Ratings for Eyegate Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.